

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in





Anti-DLL3 [SC16.15] Standard Size Ab03574-10.3

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques.

Isotype and Format: Human IgG1, Fc Silent[™], Kappa

Clone Number: SC16.15

Alternative Name(s) of Target: Delta-like protein 3; Drosophila Delta homolog 3 (Delta3)

UniProt Accession Number of Target Protein: Q9NYJ7 Published Application(s): functional assay, ELISA, FC

Published Species Reactivity: Rat, Human, Cynomolgus Monkey, Mouse

Immunogen: The original antibody was generated by immunizing three strains of mice (Balb/c, CD-1 and

FVB) with recombinant human DLL3-Fc or with human DLL3-His fusion constructs.

Specificity: This antibody binds human DLL3 in the N-terminal domain and also reacts with mouse, rat and cynomolgus monkey DLL3. Delta-like protein 3 (DLL3) is a transmembrane protein that belongs to the Delta/Serrate/Lag-2 (DSL) family of Notch ligands. Mature human DLL3 consists of a 466 amino acid (aa) extracellular domain (ECD) with one DSL domain and six EGF-like repeats, a 21 aa transmembrane segment, and a 105 aa cytoplasmic domain. It is an inhibitory Notch ligand that is highly expressed in small cell lung cancer (SCLC) and other neuroendocrine tumors but minimally expressed in normal tissues. It is therefore being explored as a potential therapeutic target in SCLC.

Application Notes: The binding characterization of this antibody to human DLL3 was done using ELISA. Binding affinity of mouse IgG antibody for human DLL3 is Kd= 0.2 nM. This antibody can bind human, cynomolgus monkey, rat and mouse DLL3 expressed on surface of 293 cells via flow cytometry. This antibody can mediate killing of tumor cells expressing DLL3 and facilitate the delivery of cytotoxic agents to live cells, in an vitro cell killing assay. This antibody was capable of killing OV26 cells, an ovarian NET NTX tumor, with a sub-picomolar EC50 (e.g. 0.14 pM). Humanized version of this antibody is also available on request. Human IgG1 version was capable of killing LU37 cells in an in vitro killing assay. This antibody was used for the generation of antibody-drug conjugates for suppressing tumor growth (US9089615). It was also used in combination with OKT3 for generation of a bispecific antibody targeting DLL3 and CD3. It was also used for the generation of DLL3-targeted CAR-T cells (PMID: 32554616).

Antibody First Published in:

PMID:

Note on publication:

Product Form

Size: 100 μg Purified antibody.

Purification: Protein A affinity purified **Supplied In:** PBS with 0.02% Proclin 300.

Storage Recommendation: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -

20°C.

Concentration: 1 mg/ml.

Important note – This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.